Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year

BARCELONA, Spain, Feb. 21, 2019 /PRNewswire/ -- Grifols has earned the honor of 2019 Category Leader in IV Workflow Management in the 2019 Best in KLAS: Software & Services report for its PharmacyKeeper Verification product. 

This marks the third consecutive year the PharmacyKeeper Verification software has been recognized as the leader in the IV Workflow Management category by KLAS Research, a healthcare IT data and insight-gathering company that collects and publishes impartial research on the software and services used by healthcare providers and payers worldwide. The PharmacyKeeper suite of software applications was developed by MedKeeper, which was acquired by Grifols in January, 2018.

Grifols PharmacyKeeper Verification mitigates risks of medication errors through defined compounding processes that include barcode validation and remote photo verification. It supports pharmacist approval with a robust audit trail and is designed to fit varying workflows without disruption. PharmacyKeeper Verification is just one of several web-based applications in the Grifols' PharmacyKeeper portfolio that are designed to improve key pharmacy operational processes and enhance patient safety in IV compounding.

"This honor is especially rewarding because it is based on honest, impartial end-user experiences and, as such, reflects success in our commitment to customer centricity," said Rob Jagt, President, Grifols Hospital Commercial Division.  "Our legacy of innovation has helped shape the healthcare industry since 1940 and is the foundation from which we are growing our distinctive portfolio of technology, services, and software focused on patient safety." 

KLAS seeks insight from decision-makers, managers, and end users about which vendors are true partners and products that are important to them. Insights represent the opinions of healthcare professionals and clinicians from more than 4,500 hospitals and 2,500 clinics, and account for 750 products and services from more than 200 vendors.

"Category Leaders are committed to providing the very best technology, service, and guidance to providers and payers. The Category Leader award carries with it the voice of thousands of providers and payers, highlighting outstanding vendors who have raised the bar," said KLAS President Adam Gale.

2017-2019 Best in KLAS: Software and Services reports, January, © KLAS 2019 https://klasresearch.com

About Grifols
Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to help them deliver expert medical care. Grifols' three main divisions – Bioscience, Diagnostic and Hospital – develop, produce and market innovative products and services that are available in more than 100 countries.

With a network of approximately 250 plasma donation centers, Grifols is a leading producer of plasma-derived medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.

Grifols is headquartered in Barcelona, Spain and has 21,000 employees in 30 countries. In 2017, sales exceeded 4,300 million euros. Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).
For more information, visit Grifols.com.

© 2019 Grifols All rights reserved February2019 HN/HP/0219/0077

SOURCE Grifols

Related Links

http://www.grifols.com